期刊文献+

不同剂量硫酸氯吡格雷治疗缺血性脑卒中的疗效与安全性比较 被引量:5

下载PDF
导出
摘要 目的探讨不同剂量硫酸氯吡格雷对缺血性卒中患者的疗效和安全性。方法 1 110例缺血性卒中患者随机分为两组,低剂量组(给予硫酸氯吡格雷50 mg)558例,高剂量组(给予硫酸氯吡格雷75 mg)552例。低、高剂量组分别有469例(84.1%)和457例(82.8%)完成52周的疗程,采用双盲、随机和对照的方法,通过观察患者出血情况(主要安全指标)和药物副作用(次要安全指标)评定安全性,观察患者发生的缺血性卒中、心肌梗死以及外周动脉疾病等血管血栓性疾病评定有效性。结果低、高剂量组出血副作用的发生率(分别为14.0%和16.5%)和严重副作用发生率(分别为8.6%和9.5%)差异无统计学意义(P>0.05)。低、高剂量组严重出血事件发生率分别为1.7%和1.5%(P>0.05),颅内出血比例均为0.18%;累积血栓性疾病发生率分别为2.6%和9.4%(P<0.05)。结论硫酸氯吡格雷75mg在安全性方面与50 mg差异无统计学意义,权衡药物的安全性和有效性,75 mg对预防患者缺血性卒中比50 mg剂量更具优势,值得临床应用推广。
出处 《医药导报》 CAS 北大核心 2014年第2期194-197,共4页 Herald of Medicine
  • 相关文献

参考文献3

二级参考文献56

  • 1Zhao D, Liu J, Wang W, et al. Epidemiological transition of stroke in China : twenty-one-year observational study from the Sino- MONICA-Beijing Project. Stroke,2008,39 : 1668-1674.
  • 2Algra A, Van Gijn J, Algra A, et al. Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone? J Neurol Neurosurg Psychiatry, 1999,66:557-559.
  • 3Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care,2003,26:3264-3272.
  • 4Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci, 1996,143 : 1-13.
  • 5Huang YN, Gao S, Li SW, et al. Vascular lesions in Chinese patients with transient ischemie attacks. Neurology, 1997,48:524- 525.
  • 6Wong KS, Li H. Long-term mortality and recurrent stroke risk among Chinese stroke patients with predominant intracranial atheroselerosis. Stroke, 2003,34:2361-2366.
  • 7A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996,348 : 1329-1339.
  • 8Ringleb PA, Bhatt DL, Hirsch AT, et al. Benefit of elopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke,2004,35:528-532.
  • 9Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol,2002,90:625-628.
  • 10Diener HC, Sacco RL, Yusuf S, et al. Effects of aspirin plus extended-release dipyridamole versus elopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with isehaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) trial : a double-blind, active and placebo-controlled study. Lancet Neurol,2008 ,7 :875-884.

共引文献44

同被引文献42

  • 1ELKIND M S.Epidemiology and risk factors[J].Continuum ( Minneap Minn ), 2011,17 ( 6 ) : 1213-1232.
  • 2FUKUOKA T, FURUYA D, TAKEDA H.Evaluation of clop- idogrel resistance in ischemic stroke patients [ J ]. Intern Med ,2011,50( 1 ) :31-35.
  • 3RODRIGUEZ-YANEZ M, ARIAS-RIVAS S, FERNANDEZ- FERRO J, et al. Clopidogrel and stroke [ J ]. Rev Neurol, 2011,53(9) :561-573.
  • 4SURI M F, HUSSEIN H M, ABDELMOULA M M, et al. Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke:preliminary experience [J].Med Sci Monit,2008,14(10) :139-144.
  • 5ROTHWELL P M, GILES M F, CHANDRATHEVA A, et al.Effect of urgent treatment of transient ischaemic attack and minorstroke on early recurrent stroke (EXPRESS study ) : a prospective population- based sequentialcomparison I- J .Lancet, 2007,370(9596) : 1432-1442.
  • 6MEHTA S R, TANGUAY J F, EIKELBOOM J W, et al. Double-dose versus standard- dose clopidogrel and high- dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes(CURRENT -OASIS 7):a randomised factorial trial [ J ]. Lancet, 2010,376 ( 9748 ) : 1233-1243.
  • 7DIEDLER J,AHMED N, SYKORA M, et al. Safety of intra- venous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset [ J ]. Stroke, 2010,41 (2) :288-294.
  • 8SANAK D,KULIHA M,HERZIG R,et al.Prior use of anti- platelet therapy can be associated with a higher chance for early recanalization of the occluded middle cerebral artery in acute stroke patients treated with intravenous thrombolysis[ J] .Eur Neurol,2012,67( 1 ) :52-56.
  • 9ROBERTS J D, WELLS G A, LE MAY M R.Point-of-care genetic testing for personalization of antiplatelet treatment ( RAPID GENE ) : a prospective, randomised, proof-of- concept tria/[ J] .Lancet ,2012,379(9827) : 1705-1711.
  • 10MARUYAMA H, TAKEDA H, DEMBO T, et al. Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y 12 Assay [ J ].Intern Med, 2011,50 (7) : 695-698.

引证文献5

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部